Log in

Viking Therapeutics Inc (NASDAQ:VKTX) Director Matthew W. Foehr Sells 13,000 Shares

Tuesday, June 30, 2020 | MarketBeat

Viking Therapeutics Inc (NASDAQ:VKTX) Director Matthew W. Foehr sold 13,000 shares of the business's stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $7.35, for a total value of $95,550.00. Following the sale, the director now owns 26,250 shares of the company's stock, valued at $192,937.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

VKTX traded down $0.05 during trading hours on Tuesday, reaching $7.21. The company's stock had a trading volume of 1,780,069 shares, compared to its average volume of 1,504,828. Viking Therapeutics Inc has a fifty-two week low of $3.26 and a fifty-two week high of $8.87. The stock has a market cap of $523.45 million, a PE ratio of -17.19 and a beta of 2.10. The business's 50-day moving average is $7.41 and its 200-day moving average is $6.59.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). As a group, sell-side analysts anticipate that Viking Therapeutics Inc will post -0.6 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Verus Capital Partners LLC acquired a new position in Viking Therapeutics during the fourth quarter worth $26,000. Great West Life Assurance Co. Can purchased a new position in Viking Therapeutics in the fourth quarter valued at $30,000. Arden Trust Co purchased a new position in Viking Therapeutics in the first quarter valued at $30,000. Engineers Gate Manager LP purchased a new position in shares of Viking Therapeutics during the first quarter worth about $49,000. Finally, Arizona State Retirement System acquired a new stake in shares of Viking Therapeutics during the first quarter worth about $71,000. Hedge funds and other institutional investors own 54.24% of the company's stock.

VKTX has been the subject of a number of analyst reports. BidaskClub upgraded Viking Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, April 14th. William Blair restated a "buy" rating on shares of Viking Therapeutics in a research report on Friday, April 3rd. B. Riley dropped their price target on Viking Therapeutics from $16.00 to $12.00 and set a "buy" rating for the company in a research report on Monday, May 4th. Raymond James dropped their price target on Viking Therapeutics from $41.00 to $25.00 and set a "strong-buy" rating for the company in a research report on Friday, May 1st. Finally, Chardan Capital initiated coverage on Viking Therapeutics in a research report on Tuesday, May 5th. They issued a "buy" rating and a $15.00 price target for the company. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. The stock has a consensus rating of "Buy" and a consensus price target of $14.50.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis.

Featured Story: What is a resistance level?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Best Stocks to Own Right Now

Today, we are inviting you to view our list of the seven best stocks to own for the next thirty days.

Why is it worth looking into these stocks? Some of Wall Street's most respected and most accurate research analysts have been upgrading these stocks and raising their price targets for these companies.

No, we're not talking recommendations from some no-name blogger or a junior analyst from a brokerage you've never heard of. These stocks have received multiple positive recommendations in the last 30 days from analysts that have received four star and five star rankings from MarketBeat's proprietary brokerage ranking system.

Analysts given four star and five star ratings from MarketBeat consistently issue accurate price targets and their buy recommendations often outperform the market by double digits. Buy recommendations from our current top-rated brokerage, National Securities, have gone up by an average of 47.5% in the 12 months after they were issued.

We've reviewed every research report published by these top-rated analysts in the last 90 days and have identified seven stocks that these analysts are poised for an immediate breakout.

View the "7 Best Stocks to Own Right Now".

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.